Overview
Mechanisms of N-acetylcysteine Mediated Vascular Adverse Effects
Status:
Unknown status
Unknown status
Trial end date:
2012-09-01
2012-09-01
Target enrollment:
0
0
Participant gender:
Male
Male
Summary
Paracetamol overdose is the leading cause of acute liver failure in the Western World. N-acetylcysteine (NAC) has been the antidote of choice for over 30 years but its use is associated with adverse effects in 40% of cases. Patients characteristically experience nausea, vomiting and an anaphylactoid ('pseudo-allergic') syndrome. This reaction is clinically similar to true anaphylaxis (allergic reaction) including flushing, rash, constriction of airways, and a fall in blood pressure, but occurs via a different mechanism. Although treatable, these reactions lead to patient distress, commonly cause confusion among treating physicians, and lead to significant delays in antidote administration. The aetiology of these adverse reactions to NAC remains unclear. We hypothesise: i) these reactions result from a dose-dependent release of the chemical histamine, causing dilatation of blood vessels (vasodilatation) and the anaphylactoid syndrome; ii) paracetamol conversely exerts a protective effect on the reaction, with a less severe reaction observed in the presence of higher paracetamol concentrations. We will investigate the mechanisms underlying adverse reactions to NAC in the human forearm model, examining the role of histamine and other markers involved in the inflammatory process. The wider significance is an improved understanding of this poorly delineated phenomenon, with implications for other medications associated with similar reactions, such as non-steroidal anti-inflammatory drugs and opioids such as morphine.Phase:
N/AAccepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
University of EdinburghCollaborator:
NHS LothianTreatments:
Acetaminophen
Acetylcysteine
Chlorpheniramine
Histamine
Histamine Antagonists
N-monoacetylcystine
Ranitidine
Ranitidine bismuth citrate
Criteria
Inclusion Criteria:- Healthy male, non-smoking, volunteers aged between 18-64 years
Exclusion Criteria:
- Lack of informed consent Age <18 or >64 years Current smoker Current involvement in a
clinical trial Clinically significant comorbidity: heart failure, hypertension, known
hyper-lipidaemia, diabetes mellitus, asthma, coagulopathy or bleeding disorders
Current intake of aspirin, other non-steroid anti-inflammatory medications, or
vasodilators Recent infective/inflammatory condition Recent blood donation (during the
preceding three months)